Preview

FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology

Advanced search

PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER

https://doi.org/10.17749/2070-4909.2015.8.4.040-048

Full Text:

Abstract

Objectives: To determine the clinical and economical effectiveness of influenza and pneumococcal vaccination in working adults without occupational exposures on respiratory diseases from an employer’s perspective. Methods. The study involved about 2,000 employees of the Joint Stock Company «Russian Railways» (JSCo «RZD») followed for 7 months during the 2013-2014 influenza season to collect data on influenza like illness (ILI) and pneumococcal respiratory like illness. Morbidity estimates from different observation groups was calculated using the Pearson χ2 criterion (with Bonferroni correction, if needed) and using the Marascuillo procedure. The calculations are performed in Microsoft Excel (the applied statistical software was not used). The author presented the method of direct and indirect costs calculation. Pharmacoeconomic evaluation for the JSCo «RZD» was defined according to the impact of the 2013 influenza vaccination programme (292.180 employees were vaccinated). Results. Acute respiratory morbidity was significantly lower in vaccinated employees than in nonvaccinated. The vaccine effectiveness was 73.9% against influenza and 84.6% against pneumococcal respiratory infections. The morbidity differences between tobacco smokers and non-smokers is not proven. Due 292.180 employees influenza immunization the direct costs for JSCo "RZD" amounted to 114.2 million roubles (2.54 million EUR), indirect costs estimated at 1.9 billion rubles (42.2 million EUR). According to the generated modelling, the pneumococcal (PPSV23) immunization programme became cost-effective starting from the second year after vaccination and should continue to increase. 

About the Author

D. A. Zhukov
Joint Stock Company «Russian Railways» (JSCo «RZD»), 52A/1 Malaya Gruzinskaya str., 123557 Moscow, Russia.
Russian Federation

Head of the analytical department of JSCo "RZD" medical directorate.



References

1. Influenza vaccines: WHO position paper. Weekly Epidemiological Bulletin [Grippoznye vaktsiny: dokument po pozitsii VOZ. Ezhenedel'nyi epidemiologicheskii byulleten' (In Russian)]. 2012; 87.

2. Resolution of the Chief State Sanitary Doctor of the Russian Federation of 14.08.2014 No47 [Postanovlenie Glavnogo gosudarstvennogo sanitarnogo vracha Rossiiskoi Federatsii ot 14.08.2014 No47 (In Russian)].

3. Order of Ministry of Health of the Russian Federation dated 03.21.14 No125n "On approval of the National Immunization Schedule and Calendar of preventive vaccinations for the epidemic indications" [Prikaz Ministerstva zdravookhraneniya Rossiiskoi Federatsii ot 21.03.14 No125n «Ob utverzhdenii Natsional'nogo kalendarya profilakticheskikh privivok i Kalendarya profilakticheskikh privivok po epidemicheskim pokazaniyam» (In Russian)].

4. Khabibov A.N. The effectiveness of the program "Health" in Russia's largest coal company. Report of the international conference "Effective Health Care: socially oriented business the future of industrial medicine" [Effektivnost' programmy «Zdorov'e» v krupneishei rossiiskoi ugol'noi kompanii. Doklad na mezhdunarodnoi konferentsii «Effektivnoe zdravookhranenie: sotsial'no orientirovannyi biznes – budushchee promyshlennoi meditsiny» (In Russian)]. Moscow. 2012.

5. Report on health status and health organizations on the basis of the executive bodies of subjects of the Russian Federation for 2013 [Doklad o sostoyanii zdorov'ya naseleniya i organizatsii zdravookhraneniya po itogam deyatel'nosti organov ispolnitel'noi vlasti sub"ektov Rossiiskoi Federatsii za 2013 g (In Russian)]. Moscow. 2013.

6. Letter Rospotrebnadzor from 30.06.2014 No01 / 7281-14-32 «On the results of epidemiological season influenza and SARS 2013/2014. [Pis'mo Rospotrebnadzora ot 30.06.2014 No01/7281-1432 «Ob itogakh epidsezona po grippu i ORVI 2013/2014(In Russian)]. Moscow. 2014.

7. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst. Rev. 2013; 1: CD000422.

8. Musher D., Manoff S., McFetridge R. et al. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults. Hum. Vaccin. 2011; 9: 919-928.


For citation:


Zhukov D.A. PHARMACOECONOMIC EVALUATION OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN EMPLOYEES OF THE JOINT STOCK COMPANY "RUSSIAN RAILWAYS" (JSCO "RZD") ON INVESTMENT FOR THE EMPLOYER. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2015;8(4):40-48. (In Russ.) https://doi.org/10.17749/2070-4909.2015.8.4.040-048

Views: 303


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)